Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226–40. https://doi.org/10.1016/S1473-3099(20)30796-9.

Article  CAS  PubMed  Google Scholar 

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–28. https://doi.org/10.1016/S1473-3099(18)30554-1.

Article  CAS  PubMed  Google Scholar 

Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213–25. https://doi.org/10.1016/S1473-3099(20)30731-3.

Article  CAS  PubMed  Google Scholar 

Galani I, Papoutsaki V, Karaiskos I, Moustakas N, Galani L, Maraki S, Mavromanolaki VE, Legga O, Fountoulis K, Platsouka ED, Giannopoulou P, Papadogeorgaki H, Damala M, Chinou E, Pasxali A, Deliolanis I, Vagiakou H, Petinaki E, Chli A, Vagdatli E, Kazila P, Papaioannou V, Kontopoulou K, Ferke AN, Moraitou E, Antoniadou A, Giamarellou H. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter study. Eur J Clin Microbiol Infect Dis. 2023;42:843–52. https://doi.org/10.1007/s10096-023-04616-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, Patel S, Mendes RE, Wenzler E. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020;64:e00559-e620. https://doi.org/10.1128/AAC.00559-20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Risco-Risco C, Henriquez-Camacho C, Herrera-Rueda M, Barberán J, Andaluz-Ojeda D. Cefiderocol versus best available therapy in the treatment of critically ill patients with severe infections due to resistant Gram-negative bacteria: a systematic review and meta-analysis. Antibiotics (Basel). 2024;13:1048. https://doi.org/10.3390/antibiotics13111048.

Article  CAS  PubMed  Google Scholar 

Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. J Glob Antimicrob Resist. 2024;38:12–20. https://doi.org/10.1016/j.jgar.2024.05.009.

Article  CAS  PubMed  Google Scholar 

Bianco G, Boattini M, Cricca M, Diella L, Gatti M, Rossi L, Bartoletti M, Sambri V, Signoretto C, Fonnesu R, Comini S, Gaibani P. Updates on the activity, efficacy and emerging mechanisms of resistance to cefiderocol. Curr Issues Mol Biol. 2024;46:14132–53. https://doi.org/10.3390/cimb46120846.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rando E, Novy E, Sangiorgi F, De Pascale G, Fantoni M, Murri R, Roberts JA, Cotta MO. A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant gram-negative bacteria. Int J Antimicrob Agents. 2024;64: 107266. https://doi.org/10.1016/j.ijantimicag.2024.107266.

Article  CAS  PubMed  Google Scholar 

Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62:e02163-e2217. https://doi.org/10.1128/AAC.02163-17.

Article  PubMed  PubMed Central  Google Scholar 

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71:670–7. https://doi.org/10.1093/jac/dkv402.

Article  CAS  PubMed  Google Scholar 

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019;79:271–89. https://doi.org/10.1007/s40265-019-1055-2.

Article  CAS  PubMed  Google Scholar 

Lee YR, Yeo S. Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety. Clin Drug Investig. 2020;40:901–13. https://doi.org/10.1007/s40261-020-00955-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palombo M, Bovo F, Amadesi S, Gaibani P. Synergistic activity of cefiderocol in combination with piperacillin-tazobactam, fosfomycin, ampicillin-sulbactam, imipenem-relebactam and ceftazidime-avibactam against carbapenem-resistant Gram-negative bacteria. Antibiotics (Basel). 2023;12:858. https://doi.org/10.3390/antibiotics12050858.

Article  CAS  PubMed  Google Scholar 

Polani R, De Francesco A, Tomolillo D, Artuso I, Equestre M, Trirocco R, Arcari G, Antonelli G, Villa L, Prosseda G, Visca P, Carattoli A. Cefiderocol resistance conferred by plasmid-located ferric citrate transport system in KPC-producing Klebsiella pneumoniae. Emerg Infect Dis. 2025;31:123–4. https://doi.org/10.3201/eid3101.241426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deroche L, Rozenholc A, Arrivé F, Martellosio JP, Moal GL, Thille AW, Barraud O, Marchand S, Buyck JM. Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations. Int J Infect Dis. 2025;151: 107321. https://doi.org/10.1016/j.ijid.2024.107321.

Article  CAS  PubMed  Google Scholar 

Alteri C, Teri A, Liporace MF, Muscatello A, Terranova L, Schianca MC, Salari F, Orena BS, Silverj FG, Bernazzani M, Biscarini S, Renisi G, Cariani L, Matinato C, Canetta C, Bandera A, Callegaro A. Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals. Ann Clin Microbiol Antimicrob. 2024;23:104. https://doi.org/10.1186/s12941-024-00763-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong H, Fan L, Shi W, Zhu Y, Liu P, Wei D, Liu Y. Overexpression of β-lactamase genes (blaKPC, blaSHV) and novel CirA deficiencies contribute to decreased cefiderocol susceptibility in carbapenem-resistant Klebsiella pneumoniae before its approval in China. Antimicrob Agents Chemother. 2024;68: e0075424. https://doi.org/10.1128/aac.00754-24.

Article  CAS  PubMed  Google Scholar 

Shields RK, Dorazio AJ, Tiseo G, Squires KM, Leonildi A, Giordano C, Kline EG, Barnini S, Iovleva A, Griffith MP, Van Tyne D, Doi Y, Falcone M. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC Antimicrob Resist. 2024;6:dlae146. https://doi.org/10.1093/jacamr/dlae146.

Article  PubMed  PubMed Central  Google Scholar 

Longshaw C, Santerre Henriksen A, Dressel D, Malysa M, Silvestri C, Takemura M, Yamano Y, Baba T, Slover CM. Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis. Microbiol Spectr. 2023;11: e0237123. https://doi.org/10.1128/spectrum.02371-23.

Article  CAS  PubMed  Google Scholar 

Tiseo G, Galfo V, Falcone M. What is the clinical significance of “heteroresistance” in nonfermenting Gram-negative strains? Curr Opin Infect Dis. 2023;36:555–63. https://doi.org/10.1097/QCO.0000000000000964.

Article  PubMed  PubMed Central  Google Scholar 

Mezcord V, Escalante J, Nishimura B, Traglia GM, Sharma R, Vallé Q, Tuttobene MR, Subils T, Marin I, Pasteran F, Actis LA, Tolmasky ME, Bonomo RA, Rao G, Ramirez MS. Induced heteroresistance in carbapenem-resistant Acinetobacter baumannii (CRAB) via exposure to human pleural fluid (HPF) and its impact on cefiderocol susceptibility. Int J Mol Sci. 2023;24:11752. https://doi.org/10.3390/ijms241411752.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stracquadanio S, Bonomo C, Marino A, Bongiorno D, Privitera GF, Bivona DA, Mirabile A, Bonacci PG, Stefani S. Acinetobacter baumannii and cefiderocol, between cidality and adaptability. Microbiol Spectr. 2022;10: e0234722. https://doi.org/10.1128/spectrum.02347-22.

Article  CAS  PubMed